Overview

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Status:
RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Phase:

PHASE4

Details

Lead Sponsor:

Neurocrine Biosciences

Treatments:

valbenazine